Altimmune, Inc.
910 Clopper Road
Suite 210S
Gaithersburg
Maryland
20878
United States
Tel: 2406541450
Website: http://www.altimmune.com/
94 articles with Altimmune, Inc.
-
Altimmune Appoints Raymond Jordt as Chief Business Officer
1/4/2023
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023.
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
1/4/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune’s recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be held in Park City, UT on January 6-7, 2023.
-
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
12/20/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with NAFLD.
-
Altimmune to Participate at Two Upcoming Investor Conferences - November 22, 2022
11/22/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences: Evercore ISI 5th Annual HealthCONx Virtual Conference Tuesday, November 29, 2022 Fireside chat at 10:55 am Eastern Time.
-
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
11/10/2022
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three and nine months ended September 30, 2022, and provided a business update.
-
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
11/3/2022
Altimmune, Inc. today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update.
-
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®
10/28/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022.
-
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
9/28/2022
Altimmune, Inc. today announced the completion of first dosing of all subjects in its Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide 1 in subjects with obesity or overweight.
-
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
8/11/2022
Altimmune, Inc. today announced financial results for the three and six months ended June 30, 2022, and provided a business update.
-
Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11
8/4/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 and will provide a business update.
-
SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022Presentation to be highlighted in the Best of International Liver Congress
6/17/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver Congress TM 2022, to be held in London, UK on June 22-26, 2022.
-
Altimmune to Participate at Two Upcoming Investor Conferences
6/3/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in June 2022.
-
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
5/31/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medicine, will deliver an oral presentation at the 82nd American Diabetes Association (ADA) Scientific Sessions, to be held in New Orleans, LA on June 3-7, 2022.
-
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
5/20/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5 th Global NASH Congress on May 26-27, 2022, in London, UK.
-
Altimmune to Present at Upcoming Investor Conferences - May 16, 2022
5/16/2022
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate at the following investor conferences in May 2022:
-
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
5/12/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2022 and provided a corporate update.
-
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
5/5/2022
Altimmune, Inc. today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update.
-
Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.
-
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
4/1/2022
Altimmune, Inc. today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide 1 in subjects with obesity or overweight.